NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Monte Rosa Therapeutics, Inc. GLUE
6 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$123.7M
▲ 63.5% vs FY2024
EPS · FY25
—
Dividend / sh · FY25
—
Payout · FY25
-0%
ROE · FY25
-16.9%
Net margin · FY25
-31.2%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 123.7M
Revenue, FY2025 · full 6-year series below
Revenue
Net income
The company lost 31 cents on every revenue dollar this year.
Per share
—
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-16.9%
Return on equity, FY2025
ROE
Operating margin-43.8%
Net margin-31.2%
Return on assets-8.7%
Each USD of equity lost 17 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit-0.0%
Consecutive raises—
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.07B
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 448.7M
total assets, end of FY2025
Total assetsUSD 448.7M
EquityUSD 233.1M
CashUSD 129.9M
Current ratio6.12×
Equity funds 52% of total assets.
History
6 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
Revenue $B
0.1
0.1
0.0
·
·
·
Operating income $B
−0.1
−0.1
−0.1
−0.1
−0.1
−0.0
EBITDA $B
−0.0
−0.1
−0.1
−0.1
−0.1
−0.0
Income tax $B
−0.0
0.0
0.0
0.0
·
·
Net income $B
−0.0
−0.1
−0.1
−0.1
−0.1
−0.0
EPS, diluted $
·
·
·
·
−2.96
−23.65
Dividend / sh $
·
·
·
·
·
·
Payout %
−0
−0
−0
−0
−0
·
ROE %
−16.9
−36.2
−60.1
−35.1
−49.5
·
Shares out B
0.07
0.06
0.05
0.05
0.05
0.00
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
14 of 14
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed